Caduet, Smaduet! Add some wood to the fire! Posted: August 30, 2006 In an effort to stave off "Looming Brand Extinction," many drug companies are developing dual action drugs that combine a best-selling drug near patent extinction with another drug. Merck's Vytorin, which combines the lipid-lowering drugs Zocor with Zetia, is an example. Pfizer is now advertising a new dual action drug called Caduet, which combines into one pill Norvasc (for hypertension) and Lipitor (cholesterol), which is soon to go off patent. The print and TV ads for Caduet feature a hiking man split into two -- one who needs a pill for high blood pressure and another who needs a pill for high cholesterol. I have some suggestions for other combination drugs that Pfizer may soon develop -- especially a combo of 3 different drugs that can bring the wood to men rather than send men hiking in the woods! On a serious note, I also look at the problem of communicating risk information in ads for these types of multiple-action drugs. For more on this, see today's post to Pharma Marketing Blog. For more posts in related topic areas, see: Diddies and Spoofs Drug Safety Direct-to-Consumer (DTC) Advertising ED (Viagra/Levitra/Cialis), EC, Sexual Performance Drugs If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe. Enter your Email Address | Return to Pharma Marketing Blog Topics |

Special Supplement Relationship Marketing Direct, Targeted, Permission-based Marketing Builds Relationships, Increases ROI and Improves Patient Compliance This collection of Pharma Marketing News articles, blog posts, and survey results provides you with an excellent introduction to the many facets and uses of pharmaceutical relationship marketing. TABLE OF CONTENTS Order and pay for this Special Supplement now using your credit card ONLY $29.95 PDF file delivered to you by email (usually within minutes of placing your order): If you wish to be pay by check or credit card off-line, please use: Printable Order Form